{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:31:33Z","timestamp":1758479493695,"version":"3.38.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-106"],"award-info":[{"award-number":["2022-PUMCH-B-106"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-024-03410-1","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T15:24:02Z","timestamp":1741793042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A patient with Eradheim-Chester disease presenting with progressive cystic lung lesions and confirmed pulmonary artery hypertension: a case report"],"prefix":"10.1186","volume":"25","author":[{"given":"Yuxi","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"issue":"16","key":"3410_CR1","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1182\/blood.2019002766","volume":"135","author":"J Haroche","year":"2020","unstructured":"Haroche J, Cohen-Aubart F, Amoura Z. Erdheim-Chester disease. Blood. 2020;135(16):1311\u20138.","journal-title":"Blood"},{"issue":"22","key":"3410_CR2","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1182\/blood.2019003507","volume":"135","author":"G Goyal","year":"2020","unstructured":"Goyal G, Heaney ML, Collin M, Cohen-Aubart F, Vaglio A, Durham BH, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020;135(22):1929\u201345.","journal-title":"Blood"},{"issue":"1","key":"3410_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41572-021-00307-9","volume":"7","author":"KL McClain","year":"2021","unstructured":"McClain KL, Bigenwald C, Collin M, Haroche J, Marsh RA, Merad M, et al. Histiocytic disorders. Nat Reviews Disease Primers. 2021;7(1):73.","journal-title":"Nat Reviews Disease Primers"},{"issue":"3","key":"3410_CR4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","volume":"4","author":"EL Diamond","year":"2018","unstructured":"Diamond EL, Subbiah V, Lockhart AC, Blay J-Y, Puzanov I, Chau I, et al. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell histiocytosis: analysis of Data from the Histology-Independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4(3):384\u20138.","journal-title":"JAMA Oncol"},{"issue":"7","key":"3410_CR5","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1182\/blood-2016-09-740217","volume":"129","author":"TM Nordmann","year":"2017","unstructured":"Nordmann TM, Juengling FD, Recher M, Berger CT, Kalbermatten D, Wicki A, et al. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations. Blood. 2017;129(7):879\u201382.","journal-title":"Blood"},{"issue":"11","key":"3410_CR6","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1007\/s00330-018-5421-3","volume":"28","author":"SM Mirmomen","year":"2018","unstructured":"Mirmomen SM, Sirajuddin A, Nikpanah M, Symons R, Paschall AK, Papageorgiou I, et al. Thoracic involvement in Erdheim-Chester disease: computed tomography imaging findings and their association with the BRAFV600E mutation. Eur Radiol. 2018;28(11):4635\u201342.","journal-title":"Eur Radiol"},{"issue":"10","key":"3410_CR7","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.mayocp.2019.02.023","volume":"94","author":"G Goyal","year":"2019","unstructured":"Goyal G, Young JR, Koster MJ, Tobin WO, Vassallo R, Ryu JH, et al. The Mayo Clinic Histiocytosis Working Group Consensus Statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. Mayo Clin Proc. 2019;94(10):2054\u201371.","journal-title":"Mayo Clin Proc"},{"key":"3410_CR8","doi-asserted-by":"crossref","unstructured":"Haroutunian SG, O\u2019Brien KJ, Estrada-Veras JI, Yao J, Boyd LC, Mathur K et al. Clinical and histopathologic features of interstitial lung disease in Erdheim\u207bChester Disease. J Clin Med. 2018;7(9).","DOI":"10.3390\/jcm7090243"},{"issue":"6","key":"3410_CR9","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/bjh.17712","volume":"194","author":"J-N Wang","year":"2021","unstructured":"Wang J-N, Wang F-D, Sun J, Liang Z-Y, Li J, Zhou D-B, et al. Pulmonary manifestations of Erdheim-Chester disease: clinical characteristics, outcomes and comparison with Langerhans cell histiocytosis. Br J Haematol. 2021;194(6):1024\u201333.","journal-title":"Br J Haematol"},{"issue":"5","key":"3410_CR10","doi-asserted-by":"publisher","first-page":"E114","DOI":"10.1002\/ajh.25055","volume":"93","author":"F Cohen-Aubart","year":"2018","unstructured":"Cohen-Aubart F, Emile J-F, Carrat F, Helias-Rodzewicz Z, Taly V, Charlotte F, et al. Phenotypes and survival in Erdheim-Chester disease: results from a 165-patient cohort. Am J Hematol. 2018;93(5):E114\u20137.","journal-title":"Am J Hematol"},{"issue":"7","key":"3410_CR11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/modpathol.3880130","volume":"13","author":"WL Rush","year":"2000","unstructured":"Rush WL, Andriko JA, Galateau-Salle F, Brambilla E, Brambilla C, Ziany-bey I, et al. Pulmonary pathology of Erdheim-Chester disease. Mod Pathology: Official J United States Can Acad Pathol Inc. 2000;13(7):747\u201354.","journal-title":"Mod Pathology: Official J United States Can Acad Pathol Inc"},{"issue":"6","key":"3410_CR12","first-page":"552","volume":"82","author":"M Yamaguchi","year":"2011","unstructured":"Yamaguchi M, Shiota T, Kobashi Y. Erdheim-Chester disease presenting with pneumothorax. Respir Int Rev Thorac Dis. 2011;82(6):552\u20136.","journal-title":"Respir Int Rev Thorac Dis"},{"issue":"12","key":"3410_CR13","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1164\/rccm.202206-1138IM","volume":"206","author":"S Wang","year":"2022","unstructured":"Wang S, Li J, Ren Y, Liu M, Wang B, Dai H. Extensive pulmonary cyst formation in Erdheim-Chester Disease. Am J Respir Crit Care Med. 2022;206(12):1546\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"3410_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00277-023-05534-6","volume":"103","author":"K-N Shen","year":"2024","unstructured":"Shen K-N, Chang L, Niu N, Li J, Cao X-X. Pulmonary Erdheim-Chester disease successfully treated with vemurafenib. Ann Hematol. 2024;103(2):673\u20135.","journal-title":"Ann Hematol"},{"issue":"9","key":"3410_CR15","doi-asserted-by":"publisher","first-page":"e9447","DOI":"10.1002\/ccr3.9447","volume":"12","author":"SA Usmael","year":"2024","unstructured":"Usmael SA, Gebrehiywot AA, Bekele AL, Yezengaw SB, Tefera TT, Bote HB, et al. Erdheim-Chester disease: an elusive diagnosis in a 50-year-old Ethiopian man presenting with diffuse sclerotic bone lesion. Clin Case Rep. 2024;12(9):e9447.","journal-title":"Clin Case Rep"},{"issue":"11","key":"3410_CR16","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.6004\/jnccn.2021.0053","volume":"19","author":"RS Go","year":"2021","unstructured":"Go RS, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, et al. Histiocytic neoplasms, Version 2.2021, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Cancer Network: JNCCN. 2021;19(11):1277\u2013303.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"6","key":"3410_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/bloodadvances.2016001784","volume":"1","author":"JI Estrada-Veras","year":"2017","unstructured":"Estrada-Veras JI, O\u2019Brien KJ, Boyd LC, Dave RH, Durham B, Xi L, et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv. 2017;1(6):357\u201366.","journal-title":"Blood Adv"},{"issue":"8","key":"3410_CR18","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay J-Y, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726\u201336.","journal-title":"N Engl J Med"},{"issue":"4","key":"3410_CR19","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.3324\/haematol.2017.185298","volume":"103","author":"A Bhatia","year":"2018","unstructured":"Bhatia A, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, et al. Single-agent dabrafenib for BRAFV600E-mutated histiocytosis. Haematologica. 2018;103(4):e177\u201380.","journal-title":"Haematologica"},{"issue":"6","key":"3410_CR20","doi-asserted-by":"publisher","first-page":"102038","DOI":"10.1016\/j.esmoop.2023.102038","volume":"8","author":"JY Blay","year":"2023","unstructured":"Blay JY, Cropet C, Mansard S, Loriot Y, De La Fouchardi\u00e8re C, Haroche J, et al. Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma. ESMO Open. 2023;8(6):102038.","journal-title":"ESMO Open"},{"issue":"2","key":"3410_CR21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1148\/radiology.204.2.9240543","volume":"204","author":"MW Brauner","year":"1997","unstructured":"Brauner MW, Grenier P, Tijani K, Battesti JP, Valeyre D. Pulmonary langerhans cell histiocytosis: evolution of lesions on CT scans. Radiology. 1997;204(2):497\u2013502.","journal-title":"Radiology"},{"issue":"11","key":"3410_CR22","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1038\/s41375-020-0944-4","volume":"34","author":"F Pegoraro","year":"2020","unstructured":"Pegoraro F, Papo M, Maniscalco V, Charlotte F, Haroche J, Vaglio A. Erdheim-Chester disease: a rapidly evolving disease model. Leukemia. 2020;34(11):2840\u201357.","journal-title":"Leukemia"},{"issue":"10","key":"3410_CR23","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1182\/blood-2010-10-313510","volume":"117","author":"L Arnaud","year":"2011","unstructured":"Arnaud L, Gorochov G, Charlotte F, Lvovschi V, Parizot C, Larsen M, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood. 2011;117(10):2783\u201390.","journal-title":"Blood"},{"key":"3410_CR24","doi-asserted-by":"crossref","unstructured":"Elia D, Torre O, Cassandro R, Caminati A, Harari S. Ultra-rare cystic disease. Eur Respiratory Review: Official J Eur Respiratory Soc. 2020;29(157).","DOI":"10.1183\/16000617.0163-2019"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03410-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03410-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03410-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T15:24:09Z","timestamp":1741793049000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03410-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3410"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03410-1","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report was approved by the Medical Ethics Committee of PUMCH and clinical trial number was not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for publication was obtained from the patient. The patient gave written informed consent for his clinical details along with images to be published in this study by signing the consent form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}